Rapid review: Vaccination against Human Papillomavirus in children and men
DOI:
https://doi.org/10.18270/rsb.v14i1.4562Keywords:
human papillomavirus, recombinant tetravalent vaccine against human papillomavirus types 6, 11, 16, 18, papilloma virus infections, child, manAbstract
Objective: To define the status of vaccination against the human papillomavirus (HPV) in the male population (boys and men).
Material and methods: An adaptation of the Cochrane rapid review methodology was employed. The consulted databases included Medline, Embase, Central, and Lilacs, utilizing Decs terms such as “Human Papillomavirus Viruses,” “Primary Care,” “Papillomavirus Vaccines,” “Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18,” “Child,” and “man.” The review encompassed original articles, systematic reviews and case reports, focusing on children and men without comorbidities who had been immunized against HPV.
Results: Out of the 5320 articles identified, 15 were selected. Specific filters were applied including selection based on title, abstract, and final unit of analysis. The efficacy of the vaccine in preventing HPV infection is highlighted, along with its safety and tolerance in both adult and pediatric populations.
Conclusion: Vaccination against HPV holds paramount importance in public health as an effective measure to combat the spread of the virus and its complications. HPV vaccination in children is posited as a successful strategy with a heightened preventive impact, particularly in individuals who have not initiated sexual activity. Future research should focus on assessing the nationwide impact of HPV vaccination.
Downloads
References
Soheili M, Keyvani H, Nasseri S. Human papilloma virus: A review study of epidemiology, carcinogenesis, diagnostic methods, and treatment of all HPV-related cancers. Med J Islam Repub Iran. 2021; 35:65. https://doi.org/10.47176/mjiri.35.65
Nelson CW, Mirabello L. Human papillomavirus genomics: Understanding carcinogenicity. Tumour Virus Res. 2023; 15:200258. https://doi.org/10.1016/j.tvr.2023.200258
Word Health Organization [Web site]. Washington DC: WHO; 1 September 2023. One in three men worldwide are infected with genital human papillomavirus. Available in: https://www.who.int/news/item/01-09-2023-one-in-three-men-worldwide-are-infected-with-genital-human-papillomavirus#:~:text=A%20new%20study%20has%20been,%2C%20or%20oncogenic%2C%20HPV%20types.
Meites E, Wilkin TJ, Markowitz LE. Review of human papillomavirus (HPV) burden and HPV vaccination for gay, bisexual, and other men who have sex with men and transgender women in the United States. Hum Vaccin Immunother. 2022;18(1):2016007. https://doi.org/10.1080/21645515.2021.2016007
Ministerio de Salud y Protección Social. Vacunación contra el Virus Papiloma humano-VPH en Colombia, para la prevención del cáncer de cuello uterino y verrugas genitales- Documento informativo para personal del área de la salud. Bogotá DC: MinSalud, Instituto Nacional de Cancerología, INS; 2012
Ministerio de salud y protección social, Dirección de Promoción y Prevención Subdirección de enfermedades transmisibles, Grupo de Enfermedades Inmunoprevenibles. Lineamientos técnicos y operativos para la vacunación contra el virus del papiloma humano (VPH). Guía de práctica clínica para la detección y manejo de lesiones precancerosas de cuello uterino. Guía para pacientes y cuidadores. Bogotá DC: MinSalud; 2012
Palencia-Sánchez F, Echeverry-Coral SJ. Aspectos sociales que han afectado la aceptación de la vacunación contra el Virus del Papiloma Humano en Colombia. Una revisión sistemática. Rev Colomb Obstet Ginec. 2020;71(2):178-94. https://doi.org/10.18597/rcog.3448
Proyecto de Ley 033 de 2023; Por medio de la cual se amplía la cobertura de vacunación gratuita contra el Virus del Papiloma Humano (VPH). Bogotá DC; Congreso de la República de Colombia – Senado; 2023.
Garritty C, Gartlehner G, Nussbaumer-Streit B, King VJ, Hamel C, Kamel C, Affengruber L, Stevens A. Cochrane Rapid Reviews Methods Group offers evidence-informed guidance to conduct rapid reviews. J Clin Epidemiol. 2021; 130:13-22. https://doi.org/10.1016/j.jclinepi.2020.10.00.
JBI. Critical appraisal tools [internet]. Adelaide, JBI; n.d. Available from: https://jbi.global/critical-appraisal-tools
Joanna Briggs Institute. Levels of Evidence. Australia: JBI- Global; 2014. Available in: https://jbi.global/sites/default/files/2019-05/JBI-Levels-of-evidence_2014_0.pdf.
Laserson AK, Oliffe JL, Krist J, Kelly MT. HPV Vaccine and college-age men: a scoping review. Am J Mens Health. 2020;14(6):1557988320973826. https://doi.org/10.1177/1557988320973826
Mauskopf J, Blake L, Eiden A, Roberts C, Hu T, Nyaku M. Economic evaluation of vaccination programs: a guide for selecting modeling approaches. Value Health. 2022;25(5):810-23. https://doi.org/10.1016/j.jval.2021.10.017
Mennini FS, Silenzi A, Marcellusi A, Conversano M, Siddu A, Rezza G. HPV vaccination during the COVID-19 pandemic in Italy: opportunity loss or incremental cost. Vaccines (Basel). 2022; 10(7):1133. https://doi.org/10.3390/vaccines10071133
Meisman AR, Sachdeva YS, Real FJ, Kahn J, Rosen BL. Association between social determinants of health and completion of the HPV vaccine series. Abst 170. J. Adolesc. Health. 2023;72(3): S95-S6.
Moreira ED, Giuliano AR, de Hoon J, Iversen OE, Joura EA, Restrepo J, Van Damme P, Vandermeulen C, Ellison MC, Krick A, Shields C, Heiles B, Luxembourg A. Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients andin men 16 to 26 years of age. Hum Vaccin Immunother. 2018;14(2):396-403. https://doi.org/10.1080/21645515.2017.1403700
Goldstone SE. Human papillomavirus (HPV) vaccines in adults: Learnings from long-term follow-up of quadrivalent HPV vaccine clinical trials. Hum Vaccin Immunother. 2023;19(1):2184760. https://doi.org/10.1080/21645515.2023.2184760
Garland SM, Pitisuttithum P, Ngan HYS, Cho CH, Lee CY, Chen CA, et al. Efficacy, immunogenicity, and safety of a 9-Valent human papillomavirus vaccine: subgroup analysis of participants from Asian countries. J Infect Dis. 2018;218(1):95-108. https://doi.org/10.1093/infdis/jiy133
Wang Z, Lau JTF, Ip TKM, Yu Y, Fong F, Fang Y, Mo PKH. Two web-based and theory-based interventions with and without brief motivational interviewing in the promotion of human papillomavirus vaccination among Chinese men who have sex with men: randomized controlled trial. J Med Internet Res. 2021;23(2): e21465. https://doi.org/10.2196/21465
Rosado C, Fernandes AR, Gonçalves-Rodrigues A, Lisboa C. Impact of human papillomavirus vaccination on male disease: a systematic review. Vaccines (Basel). 2023; 11(6):1083. https://doi.org/10.3390/vaccines11061083
Shin H, Jeon S, Cho I, Park H. Factors affecting human papillomavirus vaccination in men: systematic review. JMIR Public Health Surveill. 2022;8(4): e34070. https://doi.org/10.2196/34070
Guo Y, Bowling J. Human papillomavirus (HPV) vaccination initiation and completion among adult males in the United States. J Am Board Fam Med. 2020; 33(4):592-9. https://doi.org/10.3122/jabfm.2020.04.190464
Escoffery C, Petagna C, Agnone C, Perez S, Saber LB, Ryan G, Dhir M, Sekar S, Yeager KA, Biddell CB, Madhivanan P, Lee S, English AS, Savas L, Daly E, Vu T, Fernandez ME. A systematic review of interventions to promote HPV vaccination globally. BMC Public Health. 2023;23(1):1262. https://doi.org/10.1186/s12889-023-15876-5
Amantea C, Foschi N, Gavi F, Borrelli I, Rossi MF, Spuntarelli V, Russo P, Gualano MR, Santoro PE, Moscato U. HPV vaccination adherence in working-age men: a systematic review and meta-analysis. Vaccines (Basel). 2023;11(2):443. https://doi.org/10.3390/vaccines11020443
Urrutia MT, Araya AX, Gajardo M, Chepo M, Torres R, Schilling A. Acceptability of HPV vaccines: a qualitative systematic review and meta-summary. Vaccines (Basel). 2023; 11(9):1486. https://doi.org/10.3390/vaccines11091486
Grandahl M, Nevéus T. Barriers towards HPV vaccinations for boys and young men: a narrative review. Viruses. 2021; 19; 13(8):1644. https://doi.org/10.3390/v13081644
Bruni L, Albero G, Rowley J, Alemany L, Arbyn M, Giuliano AR, Markowitz LE, Broutet N, Taylor M. Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis. Lancet Glob Health. 2023;11(9): e1345-e62. https://doi.org/10.1016/S2214-109X(23)00305-4
Patel C, Brotherton JM, Pillsbury A, Jayasinghe S, Donovan B, Macartney K, Marshall H.The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Euro Surveill. 2018; 23(41):1700737. https://doi.org/10.2807/1560-7917.ES.2018.23.41.1700737
Kempe A, O’Leary ST, Markowitz LE, Crane LA, Hurley LP, Brtnikova M, Beaty BL, Meites E, Stokley S, Lindley MC. HPV vaccine delivery practices by primary care physicians. Pediatrics. 2019; 144(4): e20191475. https://doi.org/10.1542/peds.2019-1475
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Universidad El Bosque
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The authors will submit a statement attesting to the authenticity of the material, attaching signature and id number. It is also required that they submit a statement surrendering economic rights to El Bosque University